Among current anti-diabetic drugs, dipeptidyl peptidase (DPP) 4 inhibitors [109], SGLT2 inhibitors [109,110], and thiazolidinediones [111] have been reported to have pleiotropic anti-inflammatory activity by reducing NLRP3 activation in DKD experimental models, independently of their glucose lowering effect. The gene discussed is NLRP3; the disease is diabetic kidney disease.